Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of PCI-32765, both as a
single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and
refractory Multiple Myeloma (MM)